Today the Cancer Moonshot Blue Ribbon Panel submitted its report to the National Cancer Advisory Board (H/T The Guardian). Appointed in April, the panel was tasked with providing recommendations on how to best advance the broad goals of the Cancer Moonshot, which is focused on improving detection, treatment and prevention of cancer. Specifically, the Moonshot is focused on better using the existing resources of public and private entities involved in cancer research and treatment to make it accelerate advances against the various forms of the disease.
The panel divided the topic into seven broad topics, and there are recommendations in the report from each area. They are:
- Clinical Trials
- Enhanced Data Sharing
- Cancer Immunology
- Implementation Science
- Pediatric Cancer
- Precision Prevention and Early Detection
- Tumor Evolution and Progression
Where practical, some recommendations were merged into the final draft. A common theme in many of the recommendations was the sharing of information and the increasing of communication between parties that aren’t currently doing so. Another common theme was the development of promising research resources as well as specific therapies and/or technologies. The recommendations (consult the report for additional details) are:
- Network for Direct Patient Engagement
- Cancer Immnotherapy Clinical Trials Network
- Therapeutic Target Identification to Overcome Drug Resistance
- A National Cancer Data Ecosystem for Sharing and Analysis
- Fusion Oncoproteins in Childhood Cancers
- Symptom Management Research
- Prevention and Early Detection: Implementation of Evidence-Based Approaches
- Retrospective Analysis of Biospecimens from Patients Treated with Standard of Care
- Generation of Human Tumor Atlases
- Development of New Enabling Cancer Technologies
The panel also identified some policy issues that will pose challenges to implementing the recommendations. The issues aren’t part of their report, but they have been forwarded to the Vice President’s task force and other relevant entities. Those policy issues aren’t discussed in detail in the report (you can find some discussion of them in the recommendations), but are:
-
Coverage and reimbursement
-
Privacy and consent with regard to patient data
-
Fragmentation of the delivery of patient care in the community
-
The need to improve the clinical trials system
-
Incentives to encourage pediatric drug development
-
New federal research funding models
-
Barriers to data sharing
Critical to all of these issues and recommendations is funding for the Cancer Moonshot. But that may not come. As ScienceInsider reports, neither the House nor the Senate appropriations legislation contains anything resembling the $680 million requested by the Obama Administration to support the Moonshot. Depending on how this year’s kabuki theater/budget brinksmanship unfolds, there may be a new President by the time Congress has fully funded the government for the 2017 Fiscal Year (which starts this October 1).
While developed by cancer experts, the recommendations are presented in a way that should be accessible for all audiences, even the lay public that does not have direct or indirect (through family or friends) experience with the disease. I’d encourage other report-generating bodies to copy that style when practical for their own work.
The National Cancer Institute has more material on the report and the panel
at its website, including videos for each of the recommendations.